AGM Statement
February 03 2006 - 10:31AM
UK Regulatory
RNS Number:9210X
Cambridge Antibody Tech Group PLC
03 February 2006
FOR IMMEDIATE RELEASE
15.30 GMT, 10.30 EST Friday 3 February 2006
For further information contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 1223 471 471 Tel: +44 (0) 20 7067 0700
Peter Chambr , Chief Executive Officer Kevin Smith
John Aston, Chief Financial Officer Yvonne Alexander
Rowena Gardner, Director of Corporate Communications Rachel Taylor
BMC Communications/The Trout Group (USA)
Tel: 001 212 477 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext 15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC REPORTS OUTCOME OF 2006 ANNUAL GENERAL
MEETING
Cambridge, UK: Cambridge Antibody Technology (LSE: CAT, NASDAQ: CATG) reports
that at its Annual General Meeting, held at 13.00 GMT on Friday 3 February 2006,
Resolutions 1 to 11 and 13 to 14 were duly passed on a show of hands. Resolution
12 was conditional upon Resolution 11 having not been passed, therefore it was
withdrawn.
For information, details of the proxy voting figures will be available on the
CAT website (www.cambridgeantibody.com/html/investor_relations) from 17.00 GMT
today.
-ENDS-
Notes to Editors:
Business:
* CAT is a biopharmaceutical company, aiming to bring improvements to seriously
ill patients' lives and thereby create outstanding returns for shareholders.
CAT seeks to develop products independently and in collaboration with partners,
using its capabilities and technologies in the discovery and development of
new and innovative antibody medicines in selected therapeutic areas. CAT also
seeks to licence its technologies to enable others to develop new medicines.
Products:
* HUMIRA(R), licensed to Abbott, is the first CAT-derived antibody to be
approved for marketing. It was isolated and optimised in collaboration with
Abbott and has been approved for marketing as a treatment for rheumatoid
arthritis (RA) in 57 countries, and for psoriatic arthritis and early RA in
some European countries and the US.
* There are six further CAT-derived antibodies licensed to partners at various
stages of clinical development: ABT-874 (Abbott), LymphoStat-B(TM), HGS-ETR1,
HGS-ETR2, ABthrax(TM) (all Human Genome Sciences (HGSI)) and MYO-029 (Wyeth).
CAT has also licensed its proprietary technologies and patents to several
companies. CATOs licensees include Amgen, Chugai, Dyax, Genzyme, HGSI,
Merck & Co, Micromet, Pfizer and Wyeth, and three antibody drug candidates are
in clinical development at patent licensees.
* There are three further human therapeutic product candidates in clinical
development: CAT-354 and CAT-3888, proprietary CAT products, and GC-1008, in
collaboration with Genzyme.
Collaborations:
* CAT has a broad collaboration with Genzyme for the development and
commercialisation of antibodies directed against TGF beta, a family of proteins
associated with fibrosis and scarring, and with potential application in the
treatment of some cancers.
* CAT has a major strategic alliance with AstraZeneca to discover and develop
human antibody therapeutics, principally in inflammatory disorders. This
provides CAT with the opportunity to build a substantial pipeline of antibody
therapeutics with a significant pharmaceutical partner.
* CAT has a co-development collaboration with Amrad against GM-CSF Receptor, a
potential drug target in the development of RA.
Science:
* CAT has an advanced proprietary technology for rapidly isolating human
monoclonal antibodies using Phage Display and Ribosome Display systems. CAT
has extensive phage antibody libraries, currently incorporating more than
100 billion distinct antibodies, which form the basis for the Company's
strategy to develop a portfolio of antibody-based drugs.
Business Background:
* CAT is based near Cambridge, UK, with a new site in Palo Alto, USA. CAT
currently employs around 290 people.
* CAT is listed on the London Stock Exchange (CAT) and on NASDAQ (CATG).
* More information can be found at www.cambridgeantibody.com
Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All statements
other than statements of historical facts included in this press release may be
forward looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934. These forward looking statements are based on numerous
assumptions regarding the company's present and future business strategies and
the environment in which the company will operate in the future. Certain factors
that could cause the company's actual results, performance or achievements to
differ materially from those in the forward looking statements include: market
conditions, CAT's ability to enter into and maintain collaborative arrangements,
success of product candidates in clinical trials, regulatory developments and
competition. We caution investors not to place undue reliance on the forward
looking statements contained in this press release. These statements speak only
as of the date of this press release, and we undertake no obligation to update
or revise the statements.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMUOUVRNWRURAR_SN_RNS9210X_SU_RNSTEST_XX_153056.6236_RZ__RT_R.xRoute.001
~
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jul 2023 to Jul 2024
